^
Association details:
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
Published date:
09/15/2020
Excerpt:
Lorlatinib is a subsequent therapy option for select patients with ALK-positive NSCLC after progression on either alectinib, brigatinib, or certinib depending on the type of progression.
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China

Excerpt:
...Evidence of histologically or cytologically confirmed diagnosis of locally advanced or metastatic ALK positive NSCLC where ALK status has been previously established by the Ventana ALK (D5F3) CDx Assay (Roche Diagnostics), the Vysis ALK Break Apart FISH Probe Kit (Abbott Molecular), or the EML4 ALK Fusion Gene Detection Kit (AmoyDx)....
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
New
Title:

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study

Excerpt:
In ALK-positive patients with at least one previous ALK tyrosine kinase inhibitor (EXP2-5), objective responses were achieved in 93 (47·0%; 39·9-54·2) of 198 patients and objective intracranial response in those with measurable baseline CNS lesions in 51 (63·0%; 51·5-73·4) of 81 patients.
DOI:
10.1016/S1470-2045(18)30649-1
Trial ID: